Development of a Robust Manufacturing Route for Molnupiravir, an Antiviral for the Treatment of COVID-19-Reference-Cited by-同舟云学术

Development of a Robust Manufacturing Route for Molnupiravir, an Antiviral for the Treatment of COVID-19

Published:2021-12-10 Issue:12 Volume:25 Page:2806-2815
ISSN:1083-6160
Container-title:Organic Process Research & Development
language:en
Short-container-title:Org. Process Res. Dev.

Author:

Fier Patrick S.¹^ORCID,Xu Yingju¹,Poirier Marc¹,Brito Gilmar¹,Zheng Michelle¹,Bade Rachel¹^ORCID,Sirota Eric¹^ORCID,Stone Kevin¹,Tan Lushi¹,Humphrey Guy R.¹^ORCID,Chang Darryl¹,Bothe Jameson¹,Zhang Yongqian¹,Bernardoni Frank¹,Castro Steve¹,Zompa Michael A.¹^ORCID,Taylor Jerry¹,Sirk Kevin M.¹,Diaz-Santana Anthony¹,Diribe Ike¹,Emerson Khateeta M.¹^ORCID,Krishnamurthi Bharath¹,Zhao Ralph¹^ORCID,Ward Michael¹,Xiao Chengqian²,Ouyand Honggui²,Zhan Jianfeng²,Morris William J.¹^ORCID

Affiliation:

1. Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States

2. WuXi AppTec Co., Ltd., WaiGaoQiao Free Trade Zone, Shanghai 200131, China

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Physical and Theoretical Chemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.oprd.1c00400

Reference17 articles.

1. Merck and Ridgeback Bio Collaborate to Advance Development of Novel Antiviral Candidate, EIDD-2801. https://www.businesswire.com/news/home/20200526005229/en/ (Accessed October 25, 2021).

2. Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets

3. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice

4. SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801

5. Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study; Press Release from Merck & Co., Inc., 2021. Oct 1st.

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrative Molecular Structure Elucidation and Construction of an Extended Metabolic Pathway Associated with an Ancient Innate Immune Response in COVID-19 Patients;Journal of Proteome Research;2024-02-04

2. Ultra‐high‐performance liquid chromatography method development for the quantification of Molnupiravir and its process‐related impurities using Box‐Behnken experimental design;SEPARATION SCIENCE PLUS;2024-02

3. Overview of Recent Scale-Ups in Organic Electrosynthesis (2000–2023);Organic Process Research & Development;2024-01-18

4. Streamlined Chemo-Enzymatic Synthesis of Molnupiravir via Lipase Catalyst;ACS Omega;2024-01-17

5. Two short approaches to the COVID-19 drug β-d-N⁴-hydroxycytidine and its prodrug molnupiravir;Organic & Biomolecular Chemistry;2024